Higher net result than 95% of companies in pharmaceuticals. The sector median is €1.1m, over 61 companies.
Standalone figures, without subsidiaries
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 331 companies had the same profile as GlaxoSmithKline Biologicals has now. Each dot is one company, two years later.
97.6%
were still trading
2.4%
stopped another way
0.0%
went bankrupt
Large
20 years or older
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.4%
0.5%
3
0.6%
0.6%
4
0.7%
0.8%
5
0.9%
1.0%
6
1.4%
1.6%
7
1.7%
1.8%
8
1.9%
2.0%
9
3.1%
3.3%
10
5.9%
6.4%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 331 companies, not a prediction for GlaxoSmithKline Biologicals. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
2 directors appointed, 1 statutory auditor appointed, 2 resignations, 8 reappointmentsName hiddenVisible after signing in and Hidden nameVisible after signing in resign · Name after signing inVisible after signing in, Name hiddenVisible after signing in and Hidden nameVisible after signing in (statutory auditor) appointed · Name after signing inVisible after signing in, Name hiddenVisible after signing in, Hidden nameVisible after signing in, Name after signing inVisible after signing in, Name hiddenVisible after signing in, Hidden nameVisible after signing in and 2 others reappointed · General meeting of 24-06-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0440872918
2 directors appointed, 1 resignationName after signing inVisible after signing in and Name hiddenVisible after signing in (mandate holder) appointed · Hidden nameVisible after signing in resigns as managing director · Board meeting of 02-04-2026 · Gazette deed
3 directors appointed, 1 resignationName after signing inVisible after signing in resigns as managing director · Name hiddenVisible after signing in, Hidden nameVisible after signing in (managing director) and Name after signing inVisible after signing in (managing director) appointed · Board meeting of 02-09-2025 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
Grey: the largest companies of the sector (pharmaceuticals (NACE 21)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as GlaxoSmithKline Biologicals: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €2.5bn and €22bn, founded between 1934 and 2013.
GlaxoSmithKline Biologicals has existed since 1990. Turnover grew from €698.4m in 2003 to €7.44bn in 2025 and staff from 1,996.3 to 8,371 full-time equivalents.
Solvency fell in 2025 from 73.4% to 55.9% because of the dividend.
In 2023, three directors stepped down. In November 2025, the Official Gazette published the appointment of Name hiddenVisible after signing in as managing director.
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of GlaxoSmithKline Biologicals?
GlaxoSmithKline Biologicals is a public limited company (NV).
When was GlaxoSmithKline Biologicals founded?
GlaxoSmithKline Biologicals was founded on 01-07-1990.
Is GlaxoSmithKline Biologicals still active?
Yes, GlaxoSmithKline Biologicals is an active enterprise in the KBO register.
How many employees does GlaxoSmithKline Biologicals have?
GlaxoSmithKline Biologicals had an average of 8,371 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does GlaxoSmithKline Biologicals fall under?
In its 2025 annual accounts, GlaxoSmithKline Biologicals states joint committees 116 (Chemical industry) and 207 (White-collar workers in the chemical industry).
What is the turnover of GlaxoSmithKline Biologicals?
The turnover of GlaxoSmithKline Biologicals was €7.44bn in financial year 2025, according to the filed annual accounts.
Is GlaxoSmithKline Biologicals profitable?
In financial year 2025, GlaxoSmithKline Biologicals made a profit of €2.40bn.
Where can I find the annual accounts of GlaxoSmithKline Biologicals?
GlaxoSmithKline Biologicals filed 35 annual accounts with the National Bank of Belgium, the latest for financial year 2025. GlaxoSmithKline Biologicals also filed 6 sets of consolidated accounts for the group.
When are the next annual accounts of GlaxoSmithKline Biologicals due?
GlaxoSmithKline Biologicals must file the annual accounts for financial year 2026 by 31-07-2027.Timeline